UNITED STATES


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2013

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________

Commission File Number 000-53678

BIOZOOM, INC.
(Exact name of registrant as specified in its charter)

Nevada	26-0370478
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Wilhelmshoeher Allee 273A Kassel, Germany 34131
(Address of principal executive offices, including zip code)

(800) 882-1683
(Registrant’s telephone number, including area code)

n/a
(Former name, former address and former fiscal year, if changed since last report)

~~SECURITIES~~Indicate ~~AND~~by ~~EXCHANGE~~check ~~COMMISSION~~mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

~~Washington,~~Yes ~~D.C.~~x ~~20549~~No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).


Yes	x	No	o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer o	Accelerated filer ¨
Non-accelerated filer o	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).


Yes	o	No	x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

As of August 19, 2013, the issuer had 60,025,000 outstanding shares of common stock, $0.001 par value.

BIOZOOM INC.

FORM 10-Q

~~þ QUARTERLY~~For ~~REPORT~~the ~~UNDER~~Quarterly ~~SECTION~~Period 13Ended ORJune ~~15(d)~~30, ~~OF THE SECURITIES EXCHANGE ACT OF 1934~~2013

~~For the quarterly period ended December 31, 2012~~INDEX

o TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT


		Page

	PART I – FINANCIAL INFORMATION

Item 1	Financial Statements (unaudited)
	Condensed Balance Sheets	3
	Condensed Statements of Operations	4
	Condensed Statements of Cash Flows	5
	Notes to Condensed Financial Statements	6

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	8

Item 3	Quantitative and Qualitative Disclosures About Market Risk	10

Item 4	Controls and Procedures	10
	PART II – OTHER INFORMATION
Item 1	Legal Proceedings	11
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3	Defaults Upon Senior Securities	11
Item 4	Mine Safety Disclosures	11
Item 5	Other Information	11
Item 6	Exhibits	12

Signatures		12

For the transition period from _________ to _________

Commission File Number: 000-53678

ENTERTAINMENT ART, INC.

(Name of Small Business Issuer in its charter)

Nevada	26-0370478
(state or other jurisdiction of incorporation or organization)	(I.R.S. Employer I.D. No.)
5348 Vegas Drive, # 239, Las Vegas	89108
(Address of principal executive offices)	(Zip Code)

775-321-8239

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was require to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes þ No o

APPLICABLE ONLY TO CORPORATE ISSUERS

As of February 18, 2013 the registrant had 59,730,000 shares of common stock outstanding.

ENTERTAINMENT ART, INC.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)
	Balance Sheets	F-1
	Statements of Operations	F-2
	Statements of Cash Flows	F-3
	Notes to Financial Statements	F-4
Item 2.	Management Discussion & Analysis of Financial Condition and Results of Operations	4
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	7
Item 4.	Controls and Procedures	7
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	7
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	7
Item 3.	Defaults Upon Senior Securities	7
Item 4.	Submission of Matters to a Vote of Security Holders	7
Item 5.	Other information	7
Item 6.	Exhibits	8

~~ENTERTAINMENT~~PART ~~ART,~~I ~~INC.~~– FINANCIAL INFORMATION

(AITEM ~~Development~~1. ~~Stage~~FINANCIAL ~~Company)~~STATEMENTS

BIOZOOM, INC. CONDENSED ~~FINANCIAL~~CONSOLIDATED ~~STATEMENTS~~BALANCE SHEETS

December 31, 2012

ASSETS		(UNAUDITED)		(AUDITED)
		June 30, 2013		March 31, 2013
CURRENT ASSETS
Cash	$	579,906	$	973,840
Prepaid Expenses		187,511		32,500
Total Current Assets		767,417		1,006,340

NON-CURRENT ASSETS
Investments		38,087		28,137
Property and Equipment, net		22,722		21,492
Intangibles, net		223,087		204,305
Total Non-Current Assets		283,896		253,934

TOTAL ASSETS	$	1,051,313	$	1,260,274


LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES

Accrued Liabilities	$	125,942	$	124,232
Note Payable		2,500		2,500
Total Current Liabilities		128,442		126,732

TOTAL LIABILITIES		128,442		126,732

STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, $.001 par value
10,000,000 shares authorized, 1,150,000 issued and
outstanding as of June 30, 2013 and March 31, 2013		1,150		1,150

Common Stock, $.001 par value
100,000,000 shares authorized, 60,025,000
and 59,730,000 shares issued and outstanding as
of June 30, 2013 and March 31, 2013, respectively		60,025		59,730

Additional paid-in capital		1,478,121		1,360,416
Deficit accumulated during the development stage		(616,425)		(287,754)

TOTAL STOCKHOLDERS' EQUITY (DEFICIT)		922,871		1,133,542

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$	1,051,313	$	1,260,274

~~Unaudited~~The accompanying notes are an integral part of these condensed financial statements.

	Index
CONDENSED BALANCE SHEETS	F-1
CONDENSED STATEMENTS OF OPERATIONS	F-2
CONDENSED STATEMENTS OF CASH FLOWS	F-3
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS	F-4

3BIOZOOM, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

ENTERTAINMENT ART, INC.

		For the Three Months Ended June 30,				Cumulative results from inception
		2013		2012		(Jun 15, 2007) to June 30, 2013
REVENUE
Sales-Net	$	-	$	-	$	1,500
Total Revenue		-		-		1,500

EXPENSES
Cost of sales		-		-		1,500
Rent		6,382		-		19,382
Consulting Fees		-		-		9,234
Professional Fees		81,721		-		291,971
Research and Development		45,000		4,800		145,000
Other Selling, General and Administrative		195,568		1,965		263,746

Total Expenses		328,671		6,765		730,833

Net Loss from Operations	$	(328,671)	$	(6,765)	$	(729,333)

Other Income (Expense)
Extinguishment of Debt		-		-		126,875
Interest Expense		-		(1,361)		(13,967)
Total Other Income (Expense)		-		(1,361)		112,908

Net Income (Loss)	$	(328,671)	$	(8,126)	$	(616,425)

PER SHARE DATA:
Basic and diluted loss	$	-	$	-	$	-
per common share

Weighted Average
Common Shares
outstanding		59,800,604		59,730,000

(AThe ~~Development~~accompanying ~~Stage~~notes ~~Company)~~are an integral part of these condensed financial statements.

~~CONDENSED BALANCE SHEETS~~4

~~Unaudited~~BIOZOOM, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

ASSETS
		For the Three Months Ended June 30,				Cumulative results from inception
	Dec 31, 2012	Mar 31, 2012 (Audited)
		2013		2012		(Jun 15, 2007) to June 30, 2013
CURRENT ASSETS
CASH FLOW FROM OPERATING ACTIVITIES:
Cash	$ 0	$ 2,944
Net income (loss)	$	(328,671)	$	(8,126)	$	(616,425)
LIABILITIES AND STOCKHOLDER'S EQUITY (DEFICIT)
Adjustments to reconcile net income (loss) to net
CURRENT LIABILITIES
Cash provided by operating activities:
Note Payable	$ 2,500	$ 65,900
Depreciation		1,124		-		1,495
Accrued Liabilities	15,992	15,491
Amortization of intangibles		2,616		-		3,507
Loan Payable - Related Parties	-	6,500
Issuance of common stock for services		40,000		-		40,000
STOCKHOLDERS' EQUITY (DEFICIT)
Issuance of common stock for employee compensation		78,000		-		78,000
Preferred Stock, $.001 par value 10,000,000 shares authorized None issued nor outstanding	0	0
Debt extinguishment		-		-		(120,782)
Common Stock, $.001 par value 100,000,000 shares authorized 59,730,000 shares issued and outstanding	59,730	59,730
Changes in operating assets and liabilities
Additional paid-in capital	6,370	6,370
Prepaid Expenses		(155,011)		-		(187,511)
Deficit accumulated during the development stage	(84,592)	(151,047)
Accrued liabilities – related parties		-		81		(117,657)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Accrued liabilities		1,710		41		135,981
NET CASH USED IN OPERATING ACTIVITIES		(360,232)		(8,004)		(783,392)
CASH FLOW FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(2,354)		-		(2,354)
Purchase of intangible assets		(21,398)		-		(21,398)
Purchase of investments		(9,950)		-		(9,950)
NET CASH USED IN INVESTING ACTIVITIES		(33,702)		-		(33,702)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from loans payable – related parties		-		-		6,500
Proceeds from issuance of preferred stock		-		-		1,150,000
Proceeds from issuance of notes payable		-		6,000		74,400
Debt issued for research and development		-		-		100,000
Proceeds from sale of common stock		-		-		66,100
NET CASH PROVIDED BY FINANCING ACTIVITIES		-		6,000		1,397,000
NET INCREASE (DECREASE) IN CASH		(393,934)		(2,004)		579,906
CASH, BEGINNING OF PERIOD		973,840		2,944		-
CASH, END OF PERIOD	$	579,906	$	940	$	579,906
Supplemental Cash Disclosure:
Noncash investing and financing activities:
Cancellation of common shares	$	-	$	-	$	39,000
Purchase of property with debt	$	-	$	-	$	50,000
Purchase of intangibles for common stock	$	-	$	-	$	205,196

~~$ 0~~The accompanying notes are an integral part of these condensed financial statements.

~~$ 2,944~~ 5

~~The~~BIOZOOM, ~~accompanying notes are an integral part of these financial statements~~INC.

~~F-1~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~ENTERTAINMENT ART, INC.~~ (Unaudited)

(ANote ~~Development~~1 ~~Stage~~- ~~Company)~~Organization and Summary of Significant Accounting Policies

~~CONDENSED~~The ~~STATEMENTS~~Company OFand ~~OPERATIONS~~Nature of Business

~~Unaudited~~Biozoom, Inc. was incorporated on June 15, 2007 in the State of Nevada. The Company was initially focused on the business of designing, marketing and selling leather and other products. As of February 28, 2013, the Company entered into a transaction (the “Acquisition”) pursuant to which our newly formed wholly-owned Delaware subsidiary, Biozoom Technologies, Inc. acquired the tangible and intangible assets, including patents, licenses, and related assets, from three German companies (Opsolution Spectroscopic Systems GmbH, Opsolution NanoPhotonics GmbH and Opsolution GmbH, collectively the “Opsolution Entities” or “Opsolution Sellers”) and entered into a joint venture agreement with Opsolution GmbH pursuant to which Biozoom Technologies, Inc. was obligated to fund Opsolution GmbH’s additional development of technology on our behalf. The Company is now in the business of researching, developing and licensing technologies relating to the mobile remote collection of biomedical data as well as bi-lateral diagnostic communication. Specifically, we have developed a handheld device that utilizes spectroscopy, the interaction between cells and radiated energy, to measure concentrations of substances in the human body for application in the health, wellness, medical and chemical industries.

	3 months endedDec 31, 2012	3 months endedDec 31, 2011	9 months endedDec 31, 2012	9 months endedDec 31, 2011	Cumulative results from inception(Jun 15, 2007) to Dec 31, 2012
REVENUE Sales Net	$ 0	$ 0	$ 0	$ 0	$ 1,500
EXPENSES
Rent	0	0	0	0	13,000
Consulting Fees	234	0	234	0	9,234
Professional Fees	6,813	1,538	12,863	13,188	108,116
Other Selling, General and Administrative	1,360	1,891	7,480	5,161	67,155
Other Income (Expense)
Extinguishment of Debt	88,533	32,249	88,533	32,249	126,875
Interest Expense	0	(1,135)	(1,361)	(3,883)	(13,962)
Net Income (Loss)

Basis of Presentation

~~$ 80~~The condensed interim financial information of the Company as of June 30,~~126~~ 2013 and for the three month period ended June 30, 2013 and 2012 is unaudited, and the balance sheet as of March 31, 2013 is derived from audited financial statements. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense footnotes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, all adjustments that are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the three months ended June 30, 2013 are not necessarily indicative of the results that can be expected for the entire year ending March 31, 2014. The unaudited financial statements should be read in conjunction with the Company’s annual financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2013. In particular, the Company’s significant accounting policies were presented as Note 1 to the consolidated financial statements in that Annual Report.

~~$ 27,685~~Note 2 - Related Party Transactions

At December 31, 2011 the company received a loan from a related party in the amount of $ 666,~~595~~500 bearing interest at 5% per annum and is payable on demand. This note was extinguished during the fiscal year ended March 31, 2013.

During the year ended March 31, 2012, the balance of $ 1028,~~017~~600 loan payable to former related parties and the associated interest of $3,649 was recorded as extinguishment of debt income totaling $32,249.

As of the closing of the Acquisition on February 28, 2013, the Company had a $ ~~(84~~100,~~592)~~000 payable due to Opsolution GmbH pursuant to the Company’s joint venture agreement with Opsolution GmbH, and a $50,000 payable to the Opsolution Entities for the purchase of their property and equipment in the Acquisition. As of March 31, 2013, the Company had paid both of these payables in full.

~~PER~~Note ~~SHARE~~3 ~~DATA:~~– Investments

~~Basic~~As ~~and~~part ~~diluted~~of ~~loss per~~the ~~common~~purchase ~~share~~of the assets of Opsolution GmbH the Company acquired an equity interest in Opsolution NanoPhotonics. Opsolution NanoPhotonics is not consolidated as the Company is not the primary beneficiary providing the majority of financial support to Opsolution NanoPhotonics.

On February 28, 2013 the Company and Opsolution GmbH entered into a joint venture agreement to continue research and development of certain intellectual property. Upon execution of the joint venture agreement the Company is to provide funding of $ - 100,000 toward the development by Opsolution of new prototypes. An additional $50,000 is to be paid over 8 month provided Opsolution GmbH meets certain investor and performance criteria. The Company is recognizing this research and development expense as the services are performed and the expenses are incurred.

On June 14, 2013, the registrant’s wholly owned subsidiary, Biozoom Technologies, Inc. exercised its option, pursuant to its February 28, 2013 joint venture agreement with Opsolution GmbH, a German company, to acquire 19.9% of Opsolution GmbH for $ - 9,950. This investment is accounted for under the cost method.

~~$ -~~ 6

~~$ -~~ Note 4 – Preferred Stock

$ The Company’s Board of Directors may, without further action by the Company’s stockholders, from time to time, direct the issuance of any authorized but unissued or unreserved shares of preferred stock in series and at the time of issuance, determine the rights, preferences and limitations of each series. The holders of preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding- up of the Company before any payment is made to the holders of the common stock. Furthermore, the board of directors could issue preferred stock with voting and other rights that could adversely affect the voting power of the holders of the common stock.

~~Weighted~~In ~~Average Common~~connection ~~Shares outstanding~~with the Acquisition of the Opsolution assets, we have conducted an offering of 1,150,000 shares of Series A Preferred Stock for $1,150,000, or $1.00 per share, pursuant to the Series A Preferred Stock Purchase Agreement. This offering provides for a maximum offering amount of $2,000,000 for 2,000,000 shares of Series A Preferred Stock. Each share of Series A Preferred Stock is convertible into approximately seven and a half (7.5) shares of our common stock, comprising 8,625,000 shares, or up to 15,000,000 shares if the full $2,000,000 is sold.

~~59,730,000~~Note 5 - Common Stock

59On February 28,~~730~~ 2013 the Company issued 39,000,000 shares of its common stock at a value of .005 per share for the purchase of intellectual property from Opsolutions Spectroscopic Systems GmbH, Opsolution GmbH, Opsolution NanoPhotonics GmbH.

59On May 26,~~730~~ 2013, the Company issued to Brunson Chandler & Jones, PLLC (“BCJ”), the Company’s corporate counsel, 100,000 shares of common stock as part of its annual engagement with BCJ, for legal services. The fair market value of the shares as of the date of issuance was determined to be $40,000 or $.40 a share. The 100,000 shares will be amortized over one year. The term of the agreement is from April 1, 2013 through March 31, 2014.

59On June 15,~~730~~ 2013, the Company issued 195,000 shares of common stock to Totefa Dexter, Secretary of the Company, as part of his employment agreement with the Company. The Company recorded the value of the shares at $78,000 or $.40 per share.

~~59,730,000~~Note 6 – Fair Value of Financial Instruments

The ~~accompanying~~fair ~~notes~~value ~~are~~of anthe ~~integral~~Company’s ~~part~~cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and note payables approximate the carrying amount due to the short duration of these ~~financial statements~~accounts.

FNote 7-2 Loss per Share

~~ENTERTAINMENT~~Basic ~~ART~~loss per common share is based on the net loss divided by weighted average number of common shares outstanding. Diluted income or loss per share is computed using weighted average number of common shares plus dilutive common share equivalents outstanding during the period using the treasury stock method. As the Company has a net loss for the periods ended June 30, ~~INC~~2013 and 2012, any potentially dilutive shares are anti-dilutive and are thus not included into the earnings per share calculation.

(ANote ~~Development~~8 ~~Stage~~- ~~Company)~~Going Concern

~~CONDENSED~~The ~~STATEMENTS~~accompanying OFfinancial ~~CASH~~statements ~~FLOWS~~have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. As of June 30, 2013 and March 31, 2013, the Company had an accumulated deficit of $616,425 and $287,754, respectively. In addition, the Company had a net loss for the three months ended June 30, 2013 of $328,671 and negative cash flows from operations of $360,232. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

~~Unaudited~~In view of the matters described in the preceding paragraph, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to meet its financing requirements on a continuing basis, to maintain or replace present financing, to acquire additional capital from investors, and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

	9 months endedDec 31, 2012	9 months endedDec 31, 2011	Jun 15, 2007(date of inception) to Dec 31, 2012
OPERATING ACTIVITIES
Net Income (Loss)	$ 66,595	$ 10,017	$ (84,592)
Debt Extinguishment	(88,533)	(32,249)	(126,875)
Profit from extinguishment of debt Adjustments to reconcile Net Income (Loss) to netCash used in operating activities:
Increase (Decrease) in Accrued Liabilities – Related Parties	(81)	(31,306)	(18,449)
Increase (Decrease) in Accrued Liabilities	10,575	(5,952)	54,316
FINANCING ACTIVITIES
Proceeds from Loans payable – Related Parties	0	23,000	34,500
Proceeds from Notes payable	8,500	5,000	75,000
Proceeds from sale of common stock	0	0	66,100
CASH, END OF PERIOD

The Company intends to continue to serve its customers as a developer and distributor of customized computer software used in computer research. The Company intends to focus on raising additional capital and finding additional avenues to distribute its software. To the extent that any such financing involves the sale of our equity, our current stockholders could be substantially diluted. There is no assurance that we will be successful in achieving any or all of these objectives.

~~$ 0~~ 7

$ 772

$ 0

The accompanying notes are an integral part of these financial statements

F-3

ENTERTAINMENT ART, INC.

(A Development Stage Company)

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

Unaudited

December 31, 2012

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

Entertainment Art, Inc. (“the Company”) was incorporated on June 15, 2007 under the laws of the State of Nevada.

The Company has not yet generated revenues from planned principal operations and is considered a development stage company as defined in Accounting Standards Codification (“ASC”) 915. The Company intended to focus on designing, providing and selling a line of fashionable zip bags. The Company has since abandoned its business plan and is now seeking an operation with which to merge or acquire. Accordingly, the Company is now considered a blank check company. There is no assurance, however, that the Company will achieve its objectives or goals.

In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the information set forth therein. These financial statements are condensed and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

Results of operations for interim periods are not necessarily indicative of the results of operations for a full year.

The Company is a development stage company and has not commenced planned principal operations. The Company had virtually no revenues and incurred a net loss before extinguishment of debt of $21,938 for the nine months ended December 31, 2012, and a net loss before extinguishment of debt of $211,467 for the period June 15, 2007 (inception) to December 31, 2012. In addition, the Company had working capital and stockholders deficiencies of $18,492 at December 31, 2012. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

There can be no assurance that sufficient funds will be generated during the next year or thereafter from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital could force the Company to curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders.

The Company is attempting to address its lack of liquidity by raising additional funds, either in the form of debt or equity or some combination thereof. There can be no assurances that the Company will be able to raise the additional funds it requires.

The accompanying condensed financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

NOTE 2 – RELATED PARTY TRANSACTIONS

At December 31, 2012 the Company did not have any related party transactions.

NOTE 3 – NOTES PAYABLE

At December 31, 2012 and March 31, 2012 the company had notes payable in the amount of $2,500 and $71,900 respectively, bearing interest at 5% per annum and payable on demand. $71,900 of notes have been extinguished as of October 31, 2012.

F-4

ENTERTAINMENT ART, INC.

(A Development Stage Company)

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

Unaudited

December 31, 2012

NOTE 4 – PREFERRED STOCK

The Company’s Board of Directors may, without further action by the Company’s stockholders, from time to time, direct the issuance of any authorized but unissued or unreserved shares of preferred stock in series and at the time of issuance, determine the rights, preferences and limitations of each series. The holders of preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of the Company before any payment is made to the holders of the common stock. Furthermore, the board of directors could issue preferred stock with voting and other rights that could adversely affect the voting power of the holders of the common stock.

NOTE 5 – COMMON STOCK

In June 2007 the Company issued 39,600,000 shares of common stock to its Founders for $5,100.

In October 2007 the Company sold 20,130,000 shares of common stock to private investors at $.003 per share for gross proceeds of $61,000.

On September 30, 2009 the Board of Directors authorized a 33 for 1 forward split of the Company’s common stock to stockholders of record on July 8, 2009 and with a payment date of July 21, 2009. All share and per share data have been retroactively restated to reflect this recapitalization.

NOTE 6 – SUBSEQUENT EVENT

The Company has evaluated subsequent events through the date the financial statements were issued and filed with the Securities and Exchange Commission. The Company has determined that there were no such events that warrant disclosure or recognition in the financial statements.

F-5

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

AsResults ~~used~~of ~~in this Form 10-Q, references to “Entertainment Art,” Company,” “we,” “our” or “us” refer to Entertainment Art, Inc. unless the context otherwise indicates.~~Operations

~~Safe~~This ~~Harbor~~discussion ~~Statement~~contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors.

The following discussion should be read in conjunction with our financial statements, which are included elsewhere in this Form 10-Q (the “Report”). This Report contains forward-looking statements which relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Overview

We are a ~~blank~~Nevada-organized ~~check~~ company~~. The~~ ~~U.S.~~holding ~~Securities~~certain patents and ~~Exchange~~licenses ~~Commission~~to ~~(the~~technology ~~“SEC”)~~in ~~defines those companies as “any development stage company that is issuing a penny stock, within~~ the ~~meaning~~field of ~~Section~~devices ~~3(a)(51) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and~~ that ~~has~~use nospectroscopics ~~specific business plan or purpose, or has indicated that its business plan is~~ to ~~merge~~detect ~~with~~and anmeasure ~~unidentified~~substances ~~company~~within ~~or companies.” Under SEC Rule 12b-2 under~~ the ~~Securities~~body ~~Act of 1933, as amended (the “Securities Act”), we also qualify as a “shell company,” because we have no~~ or ~~nominal assets (~~other ~~than~~biological ~~cash) and no or nominal operations~~substances. ~~Many~~ ~~states~~We ~~have~~are ~~enacted~~also ~~statutes,~~developing ~~rules~~ and ~~regulations~~acquiring ~~limiting~~additional ~~the~~technologies ~~sale~~from oftime ~~securities of “blank check” companies in their respective jurisdictions. Management does not intend~~ to ~~undertake any efforts to cause a market to develop in our securities, either debt or equity, until we have successfully concluded a business combination~~time. We ~~intend to comply with the periodic reporting requirements of the Exchange Act for so long as we are subject to those requirements.~~

The Company’s ~~current~~was initially focused on the business ~~plan~~of isdesigning, tomarketing ~~attempt~~and toselling ~~identify~~leather and ~~negotiate~~other ~~with~~products. As aof ~~business~~February ~~target~~28, ~~for~~2013, the ~~merger~~Company ofentered ~~that~~into ~~entity~~a ~~with~~transaction ~~and~~(the ~~into~~“Acquisition”) ~~the~~pursuant ~~Company. In~~to ~~certain~~which ~~instances,~~our anewly ~~target~~formed ~~company~~wholly-owned ~~may~~Delaware ~~wish~~subsidiary, toBiozoom ~~become~~Technologies, aInc. ~~subsidiary~~acquired ofthe ~~ours~~tangible orand ~~may~~intangible ~~wish~~assets, toincluding ~~contribute~~patents, orlicenses, ~~sell~~and related assets, tofrom ~~the~~three ~~Company~~German ~~rather~~companies ~~than~~(Opsolution toSpectroscopic ~~merge. No~~Systems ~~assurances~~GmbH, ~~can~~Opsolution beNanoPhotonics ~~given~~GmbH ~~that~~and weOpsolution ~~will~~GmbH) beand ~~successful~~entered ininto ~~identifying~~a orjoint ~~negotiating~~venture agreement with ~~any~~Opsolution ~~target~~GmbH ~~company,~~pursuant orto which Biozoom Technologies, ifInc. wewas doobligated ~~enter~~to ~~into~~fund ~~such~~Opsolution aGmbH’s ~~business~~additional ~~combination,~~development noof ~~assurances~~technology ~~can~~on beour ~~given~~behalf. The asCompany tois now in the ~~terms~~business of aresearching, ~~business~~developing ~~combination,~~and orlicensing astechnologies relating to the ~~nature~~mobile remote collection of ~~the~~biomedical ~~target~~data ~~company~~as well as bi-lateral diagnostic communication. We ~~seek~~Specifically, towe ~~provide~~have developed a ~~method~~handheld ~~for~~device athat ~~foreign~~utilizes orspectroscopy, ~~domestic~~the ~~private~~interaction ~~company~~between tocells ~~become~~and aradiated ~~reporting~~energy, orto ~~public~~measure ~~company~~concentrations ~~whose~~of ~~securities~~substances ~~are~~in ~~qualified~~the human body for ~~trading~~application in the ~~United~~health, ~~States~~wellness, ~~secondary~~medical ~~markets~~and chemical industries.

~~The~~Results ~~address~~ of our principal executive office is c/o Ms. Sarah Deutsch, Entertainment Art, Inc. 5348 Vegas Drive, 239, Las Vegas, Nevada 89108. Our telephone number is 778-321-8239. We do not have a functioning website at this time.Operations

~~4 Liquidity~~Period ~~and~~Ended ~~Capital~~June ~~Resources~~30, 2013 Compared to Period Ended June 30, 2012

The ~~Company~~following ~~has~~table ~~limited~~sets ~~cash.~~ forth, for the periods indicated, data derived from our statements of operations:

The focus of Entertainment Art’s efforts is to acquire or develop an operating business. Despite no active operations at this time, management intends to continue in business and has no intention to liquidate the Company. Entertainment Art has considered various business alternatives including the possible acquisition of an existing business, but to date has found possible opportunities unsuitable or excessively priced. Entertainment Art does not contemplate limiting the scope of its search to any particular industry. Management has considered the risk of possible opportunities as well as their potential rewards. Management has invested time evaluating several proposals for possible acquisition or combination; however, none of these opportunities were pursued. Entertainment Art presently owns no real property and at this time has no intention of acquiring any such property. Entertainment Art’s expected expenses are comprised of professional fees, primarily incident to its reporting requirements.

		For the Three Months Ended
		June 30, 2013		June 30, 2012		Change

Revenues	$	-	$	-	$	-

Operating expenses:
Rent		6,382		-		6,382
Consulting fees		-		-		0
Professional fees		81,721		-		81,721
Research and development		45,000		4,800		40,200

Other selling, general and administrative		195,568		1,965		193,603
Total operating expenses		328,671		6,765		321,906

Loss from operations		(328,671)		(6,765)		(321,906)

Other income (expense):
Extinguishment of debt		-		-		-
Interest expense		-		(1,361)		1,361
Total other (income) expense		-		(1,361)		1,361
		(328,671)
Net income (loss)	$	(328,671)	$	(8,126)	$	(320,545)

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. Entertainment Art’s recurring losses from operations, stockholders’ deficiency and working capital deficiency, and lack of revenue generating operations, raise substantial doubt about the Company’s ability to continue as a going concern.Revenues

~~Management~~We ~~believes~~recorded ~~Entertainment~~no ~~Art~~commercial ~~will~~revenues ~~continue to incur losses and negative cash flows from operating activities~~ for the ~~foreseeable~~three ~~future~~months ~~and~~ended ~~will~~June ~~need additional equity or debt financing to sustain its operations until it can achieve profitability and positive cash flows~~30, if2013 ~~ever. Management plans to seek additional debt~~ and~~/or~~ ~~equity~~June ~~financing for Entertainment Art~~30, ~~but cannot assure that such financing will be available on acceptable terms~~2012.

~~The~~General ~~accompanying~~and ~~financial~~Administrative statements do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that management will be successful in implementing its business plan or that the successful implementation of such business plan will actually improve the Company’s operating results.Expenses

~~Plan~~Rent, professional and other selling, general and administrative expenses increased for the year ended March 31, 2013 over the year ended March 31, 2012 due to increased operations and accounting and related professional fees. Research and development increased $40,200 for the period ended June 30, 2013 over the three months ended June 30, 2012 due to our joint venture agreement with Opsolution GmbH. Other selling, general and administrative expenses increased 193,603 due to issuances of ~~Operation~~common stock for services and employee compensation as well as increased management expenses.

~~During~~Net the next 12 months, the Company intends to seek, investigate and, if such investigation warrants, acquire an interest in one or more business opportunities presented to it by persons or firms who or which desire to seek the perceived advantages of a publicly held corporation. At this time, the Company has no plan, proposal, agreement, understanding or arrangement to acquire or merge with any specific business or company, and the Company has not identified any specific business or company for investigation and evaluation. No member of management has had any material discussions with any other company with respect to any acquisition of that company.Loss

~~The~~We ~~Company~~generated ~~will~~net ~~not~~losses ~~restrict~~of ~~its~~$328,671 ~~search~~for tothe ~~any~~three ~~specific~~months ~~business~~ended June 30, ~~industry~~2013 orcompared ~~geographical~~to ~~location~~$8,126 ~~and~~for the ~~Company~~same ~~may~~period ~~participate~~ in a2012. The ~~business~~net ~~venture~~loss ofincrease ~~virtually~~was ~~any~~attributable ~~kind~~to orAcquisition ~~nature. The~~as ~~discussion~~ of ~~the~~February ~~proposed~~28, ~~plan~~2013 ofwherein ~~operation~~we ~~under~~ceased ~~this~~to ~~caption~~be ~~and~~a ~~throughout~~“shell ~~this~~company” ~~Quarterly Report is purposefully general~~ and iscommenced ~~not~~operations ~~meant~~in tothe befield ~~restrictive~~ of ~~the~~devices ~~Company’s~~that ~~virtually~~use ~~unlimited~~spectroscopy ~~discretion~~ to ~~search~~detect ~~for~~ and ~~enter~~measure ~~into~~substances ~~potential~~within ~~business~~the ~~opportunities~~body or other biological substances.

The ~~Company~~following ~~will~~tables ~~have~~set toforth ~~obtain~~key ~~funds~~components ~~in one or more private placements to finance the operation~~ of ~~any~~our ~~acquired~~balance ~~business. Persons~~sheet purchasing securities in these placements and other shareholders will likely not have the opportunity to participate in the decision relating to any acquisition. The Company’s proposed business is sometimes referred to as aof ~~“blind~~June ~~pool” because any investors will entrust their investment monies to the Company’s management before they have a chance to analyze any ultimate use to which their money may be put. Consequently~~30, ~~the~~2013 ~~Company’s potential success is heavily dependent on the Company’s management, which will have virtually unlimited discretion in searching for~~ and ~~entering~~March into a business opportunity. None of the officers and directors of the Company has had any experience in the proposed business of the Company. There can be no assurance that the Company will be able to raise any funds in private placements. In any private placement31, ~~management may purchase shares on the same terms as offered in the private placement~~2013.

The Company will not restrict its search for any specific kind of business, but may acquire a venture which is in its preliminary or development stage, which is already in operation, or in essentially any stage of its corporate life. It is currently impossible to predict the status of any business in which the Company may become engaged, in that such business may need additional capital, may merely desire to have its shares publicly traded, or may seek other perceived advantages which the Company may offer.

		June 30, 2013		March 31, 2013		Change

Current Assets	$	767,417	$	1,006,340	$	(238,923)
Property and equipment		22,722		21,492		1,230
Investments		38,087		28,137		9,950
Intangibles		223,087		204,305		18,782
Total Assets		1,051,313		1,260,274		(208,961)
Current Liabilities		128,442		126,732		1,710
Total Liabilities		128,442		126,732		1,710
Stockholders Equity (Deficit)		922,871		1,133,542		(210,671)
Total Liabilities and Deficit	$	1,051,313	$	1,260,274	$	(208,961)

5As of June 30, 2013, current assets decreased 238,923 from March 31, 2032 due to a decrease in cash related increased costs related to research and development and increased operations. Non-current assets increased due to the increase of property and equipment of $1,230, net of depreciation, an increase in investments of $9,950 and an increase in intangibles of $18,782, net of amortization. As of June 30, 2013, current liabilities increased by $1,710 from March 31, 2013 due to an increase of accrued expenses.

~~Results of Operations For the three months ended December 31, 2012 compared to the three months ended December 31, 2011 and from inception to December 31, 2012~~8

~~The~~Liquidity ~~following discussion should be read in conjunction with the condensed financial statements~~ and inCapital ~~conjunction with the Company's Form 10-K/A filed on June 19, 2012. Results for interim periods may not be indicative of results for the full year.~~Resources

NoWe ~~Revenues~~have financed our operations primarily through sales of the Company’s common and preferred stock and the issuance of Convertible Promissory Notes.

The ~~Company~~following ~~did~~tables ~~not~~sets ~~generate~~forth ~~any~~selected ~~revenues~~cash ~~for~~flow ~~the~~information ~~three~~for ~~months or nine months ended December 31, 2012 and 2011 or from inception to December 31, 2012. We are not expecting to generate any revenues in~~ the ~~future.~~periods indicated:

Expenses

		For the Three Months Ended
		June 30, 2013		June 30, 2012

Cash used in operating activities	$	(360,232)	$	(8,004)
Cash used in investing activities		(33,702)		-
Cash provided by financing activities		-		6,000

Net increase (decrease) in cash	$	(393,934)	$	(2,004)

~~During~~Going ~~the~~Concern three months ended December 31, 2012 and 2011, total operating expenses were $8,407 and $3,449, respectively. General and administrative expenses were $1,360 and $1,891, respectively. Professional fees were $6,813 and $1,538, respectively and were associated with fulfilling the Company’s SEC reporting requirements (including bookkeeping and accounting services).Consideration

~~From~~We ~~inception~~are toa ~~December~~development ~~31,~~stage ~~2012,~~company ~~total~~and ~~operating~~have ~~expense~~not ~~was~~commenced ~~$199,005,~~planned ~~comprised~~principal ofoperations. ~~cost~~We ofhad ~~sales~~no revenues and have incurred a cumulative loss of $1616,~~500,~~425 ~~rent~~for ofthe ~~$13~~period June 15,~~000,~~ ~~consulting~~2007 ~~fees~~(inception) ofto $9June 30,~~234~~ 2013. In addition, ~~professional~~the ~~fees~~Company ofexpects ~~$108,116~~its ~~and~~current ~~general~~cash ~~and~~to ~~administrative~~only ~~expense~~fund ofoperations ~~$67,155~~for six months. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

~~Net~~There ~~Income/Loss~~can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders.

~~During~~We ~~the~~are ~~three~~attempting ~~months~~to ~~ended~~address ~~December~~our ~~31,~~lack ~~2012~~of liquidity by borrowing from its officers and ~~2011,~~directors ~~our~~or ~~net~~by ~~income~~raising ~~was~~additional ~~$80~~funds,~~126~~ ~~and~~either ~~$27,685,~~in ~~respectively~~the form of debt or equity or some combination thereof. ~~This~~ ~~was~~There ~~due~~can be no assurances that we will be able to raise the ~~extinguishment~~additional offunds ~~debt~~it requires.

~~From~~Off ~~inception~~Balance toSheet ~~December 31, 2012, our net loss was $84,592.~~Arrangements

Results of Operations For the nine months ended December 31, 2012 compared to the nine months ended December 31, 2011

No Revenues

The Company did not generate any revenues for the three months or nine months ended December 31, 2012 and 2011. We are not expecting to generate any revenues in the future.

Expenses

During the nine months ended December 31, 2012 and 2011, total operating expenses were $20,577 and $18,349, respectively. General and administrative expenses were $7,480 and $5,161, respectively. Professional fees were $12,863 and $13,188, respectively and were associated with fulfilling the Company’s SEC reporting requirements (including bookkeeping and accounting services).

Net Income/Loss

During the nine months ended December 31, 2012 and 2011, our net income was $66,595 and $10,017, respectively. This was due to the extinguishment of debt.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

~~6 ITEM~~Recent ~~3. QUANTITATIVE~~Accounting ~~AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~Pronouncements

AsFrom atime ~~“smaller~~to ~~reporting~~time, ~~company”~~new asaccounting ~~defined~~pronouncements are issued by ~~Rule~~FASB ~~229~~that are adopted by the Company as of the specified effective date.~~10(f)(1)~~ If not discussed, wemanagement believes that the impact of recently issued standards, which are not ~~required~~yet toeffective, ~~provide~~will ~~the~~not ~~information~~have ~~required~~a bymaterial ~~this~~impact ~~Item~~on 3the Company’s financial statements upon adoption.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As the Company is a “smaller reporting company,” this item is not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit to the Securities and Exchange Commission under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms, and that information is accumulated and communicated to our management, including our principal executive and principal financial officer (whom we refer to in this periodic report as our Certifying Officer), as appropriate to allow timely decisions regarding required disclosure. The Company’s Chief Executive Officer and Chief Financial Officer has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the period ended June 30, 2013 covered by this Form 10-Q. Based upon such evaluation, the Chief Executive Officer and Chief Financial Officer has concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

Management’s Report on Internal Control over Financial Reporting

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the United States Securities and Exchange Commission. Our principal executive officer and principal financial officer has reviewed the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 Rules 13(a)-15(e) and 15(d)-15(e)) within the end of the period covered by this Quarterly Report on Form 10-Q and has concluded that the disclosure controls and procedures are effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported in a timely manner.

Changes in Internal Controls.

There have been no changes in the Company's internal control over financial reporting during the last quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

~~PART II - OTHER INFORMATION~~10

~~ITEM~~PART 1.II ~~LEGAL~~– ~~PROCEEDINGS~~OTHER INFORMATION

~~There~~ITEM are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company1. ~~The~~ LEGAL ~~Company’s property is not the subject of any pending legal proceedings.~~PROCEEDINGS

~~ITEM~~From 1Atime to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. ~~RISK~~As ~~FACTORS~~of August 19, 2013, there were no pending or threatened lawsuits.

AsHowever, aon June 25, 2013, the SEC announced the temporary suspension of trading in the securities of the Company “~~smaller~~because ~~reporting~~of ~~company”~~concern asthat ~~defined~~certain byBiozoom affiliates and shareholders may have unjustifiably relied upon Rule ~~229.10~~144 of the Securities Act of 1933 (f‘Securities Act’) and they, Biozoom, and others may be engaged in an unlawful distribution of securities through the OTCBB.” On July 3, 2013, the SEC filed a complaint in the U.S. District Court in Manhattan against eight defendants relating to their unlawful sale of Company securities. In the complaint, the SEC alleged that Sarah Deutsch, former sole officer and director of the Company and manager of the Company’s former majority shareholder, certified that the Company approved the issuance of a certificate to one of the defendants at a board meeting held on March 22, 2013. No such board meeting with Hardy Hoheisel and Dr. Wolfgang Koecher (1the other two directors of the Company at that time, and after June 5, 2013, the sole directors of the Company) was held, weand ~~are~~Ms. Deutsch was not ~~required~~authorized to provide any such certification. The Company’s current officers (Mr. Hoheisel, Dr. Koecher, and Tefa Dexter) and directors (Mr. Hoheisel and Dr. Koecher) are not affiliated with the ~~information~~defendants, ~~required~~were bynot ~~this~~involved ~~Item~~in 1Aany sale of the Company’s securities to the defendants, nor have they sold Company securities through the OTCBB or relied upon Rule 144 or any other exemption from registration for the resale of securities. The Company and its current officers and directors are currently investigating precisely what occurred and evaluating their options for legal recourse.


ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~None~~On May 9, 2013, the Company retained Brunson Chandler & Jones, PLLC (“BCJ”) to render corporate and securities legal advisory services (assistance with quarterly and annual reports, Form 8-K’s, employment contracts, term sheets, financing contracts, etc.) for $2,500 in cash and $10,000 in stock a quarter, as well as legal services relating to the preparation and filing of a Form S-1 registration statement for $5,000 in cash upon engagement and $5,000 in cash or $10,000 in stock upon effectiveness. After paying a year’s worth of the cash portion of the general quarterly legal fee plus the initial S-1 fee, on May 26, 2013, the Company issued BCJ 100,000 restricted shares of common stock for the $40,000 balance owed to BCJ for the quarterly legal services to be provided by BCJ through March 31, 2014. The fair market value of the shares as of the date of issuance was determined to be $40,000 or $.40 a share based on the agreed-upon value of the quarterly legal services to be provided by BCJ.

~~ITEM~~On May 21, 2013, Biozoom, Inc. (the “Company”) entered into a consulting agreement with Totefa Dexter aka Tefa Dexter, its Secretary. Under the consulting agreement, Mr. Dexter agreed to render business development and sales services to the Company, and was to receive $6,000 payable immediately, a monthly fee of $3,500, and 195,000 restricted shares of the Company’s common stock on June 15, 2013. On ~~DEFAULTS~~June ~~UPON~~15, ~~SENIOR~~2013, ~~SECURITIES~~the Company issued 195,000 restricted shares of common stock to Mr. Dexter pursuant to the agreement. The Company recorded the value of the shares at $78,000 or $.40 per share.

~~None~~The securities referenced above were issued pursuant to exemptions from registration requirements relying on Section 4(2) of the Securities Act of 1933 and upon Rule 506 of Regulation D of the Securities Act of 1933.

ITEM 43. ~~MINE~~DEFAULTS ~~SAFETY~~UPON ~~DISCLOSURES~~SENIOR SECURITIES

None.

ITEM 54. ~~OTHER~~MINE ~~INFORMATION~~SAFETY DISCLOSURES

None.

7ITEM 5. OTHER INFORMATION

~~ITEM 6~~None. ~~EXHIBITS~~

Exhibit Number	Exhibit Description
31.1	Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
EX-101.INS	XBRL Instance Document
EX-101.SCH	XBRL Taxonomy Extension Schema
EX-101.CAL	XBRL Taxonomy Extension Calculation Linkbase
EX-101.LAB	XBRL Taxonomy Extension Label Linkbase
EX-101.PRE	XBRL Taxonomy Extension Presentation Linkbase
EX-101.DEF	XBRL Taxonomy Extension Definition Linkbase

~~SIGNATURES~~ ITEM 6. EXHIBITS

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.



3.1*	Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form S-1 filed on July 18, 2008)
3.2*	By-Laws (incorporated by reference to Exhibit 3.2 to our Registration Statement on Form S-1 filed on July 18, 2008)
3.3*	Certificate of Designation for Series A Preferred Stock (incorporated by reference to Exhibit 3.1 of our Form 8-K filed on March 12, 2013).
10.1*	Asset Purchase Agreement, dated as of February 28, 2013, by and between the Company and Opsolution NanoPhotonics GmbH, Opsolution GmbH and Opsolution Spectroscopic Systems GmbH, each a German entity (incorporated by reference to Exhibit 10.1 of our Form 8-K filed on March 12, 2013)
10.2*	Assignment Agreement, dated as of February 28, 2013, by and between the Company and Opsolution NanoPhotonics GmbH (incorporated by reference to Exhibit 10.2 of our Form 8-K filed on March 12, 2013)
10.3*	Assignment Agreement dated as of February 28, 2013, by and between the Company and Opsolution Spectroscopic Systems GmbH (incorporated by reference to Exhibit 10.3 of our Form 8-K filed on March 12, 2013)
10.4*	Assignment Agreement dated as of February 28, 2013, by and between the Company and Opsolution GmbH (incorporated by reference to Exhibit 10.4 of our Form 8-K filed on March 12, 2013)
10.5*	Joint Venture Agreement, dated as of February 28, 2013, by and between the Company and Opsolution GmbH (incorporated by reference to Exhibit 10.5 of our Form 8-K filed on March 12, 2013)
10.6*	Agreement on Intellectual Property and Property Rights between Biozoom Services GmbH, Vodafone Ventures Limited, Opsolution Spectroscopic Systems GmbH, MBR Messtechnik GmbH and Opsolution GmbH (incorporated by reference to Exhibit 10.6 of our Form 8-K filed on March 12, 2013)
10.7*	Series A Preferred Stock Purchase Agreement, dated as of February 28, 2013 (incorporated by reference to Exhibit 10.7 of our Form 8-K filed on March 12, 2013).
10.8*	Exercise of Purchase Option, dated as of June 14, 2013 (incorporated by reference to Exhibit 10.1 of our Form 8-K filed on June 20, 2013)
10.9*	Employment Agreement with Hardy Hoheisel, dated as of March 15, 2013 (incorporated by reference to Exhibit 10.9 of our Form 10-K filed on July 2, 2013)
10.10*	Employment Agreement with Dr. Wolfgang Köcher, dated as of March 15, 2013 (incorporated by reference to Exhibit 10.10 of our Form 10-K filed on July 2, 2013)
10.11*	Consulting Agreement with Tefa Dexter, dated as of May 21, 2013 (incorporated by reference to Exhibit 10.11 of our Form 10-K filed on July 2, 2013)
10.12*	Scientific Advisory Board Consulting Agreement with Prof. Dr. Hasan Mukhtar, dated as of April 30, 2013 (incorporated by reference to Exhibit 10.12 of our Form 10-K filed on July 2, 2013)
10.13*	Scientific Advisory Board Consulting Agreement with Prof. Dr. Rudolf Kessler, dated as of May 5, 2013 (incorporated by reference to Exhibit 10.13 of our Form 10-K filed on July 2, 2013)
10.14*	Scientific Advisory Board Consulting Agreement with Prof. Dr. Leonard Zastrow, dated as of May 8, 2013 (incorporated by reference to Exhibit 10.14 of our Form 10-K filed on July 2, 2013)
10.15*	Scientific Advisory Board Consulting Agreement with Prof. Dr. Dr. Jürgen Lademann, dated as of May 31, 2013 (incorporated by reference to Exhibit 10.15 of our Form 10-K filed on July 2, 2013)
31.1	Certification of Principal Executive Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

	ENTERTAINMENT ART, INC.
		(REGISTRANT)
Date: February 19, 2013	/s/ Sarah Deutsch
		Sarah Deutsch
		President, Chief Executive Officer, Chief Financial Officer and Director
		(Authorized Officer for Registrant)

* Previously Filed


101.INS **		XBRL Instance Document

101.SCH **		XBRL Taxonomy Extension Schema Document

101.CAL **		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF **		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB **		XBRL Taxonomy Extension Label Linkbase Document

101.PRE **		XBRL Taxonomy Extension Presentation Linkbase Document

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	BIOZOOM, INC.

Date: August 19, 2013	By:	/s/ Hardy Hoheisel
		Title: President and Chief Executive Officer,
		Principal Executive Officer and Principal
		Accounting Officer

Filing Compare · Biozoom, Inc.